Exelixis reported Phase 3 results showing its oral TKI zanzalintinib combined with Roche’s Tecentriq reduced the risk of death by roughly 20% versus a Stivarga‑based regimen in previously treated metastatic colorectal cancer, according to an ESMO presentation. The intent‑to‑treat readout noted median overall survival of 10.9 months versus 9.4 months at about an 18‑month follow‑up. Exelixis disclosed higher rates of grade 3–4 treatment‑related adverse events in the zanzalintinib arm but framed the data as the first TKI to demonstrate an OS improvement with an immune checkpoint inhibitor in this population.